Clinical Trial

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until recurrence of the disease or intolerable toxicity, following complete tumour resection with or without adjuvant standard chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-02-06.
Status change: Not Yet Recruiting → Recruiting 2023-10-06
Trial Details
NCT Number NCT05241028
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 80 participants
Start Date 2022-05-01
Primary Completion 2027-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2023-10-10